SCHEMBL20980423

SCHEMBL20980423

NC(C=O)CCCCCC=O

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
HIF1A Q16665 1/20 0.41
FAAH O00519 2/20 0.38
TRPV1 Q8NER1 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10495366 0.90
SCHEMBL18297988 0.90
SCHEMBL11778128 0.84 TSHR (0.31) TSHR
SCHEMBL10078154 0.82 TSHR (0.39) TSHR
SCHEMBL13066988 0.82 TSHR (0.39) TSHR
SCHEMBL8487319 0.80 TSHR (0.46) TSHRHIF1AFAAHTRPV1
SCHEMBL690898 0.80 TSHR (0.46) TSHRHIF1AFAAHTRPV1
SCHEMBL13368624 0.79
SCHEMBL2610603 0.79
SCHEMBL886898 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11364200-B2 2022-06-21 US disclosed
US-11318099-B2 2022-05-03 US disclosed
CN-110637036-A Compound having affinity substance, cleavable moiety and reactive group for soluble protein, or salt thereof 味之素株式会社 2019-12-31 CN disclosed
US-20190133948-A1 FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES NITTO DENKO CORPORATION (JP) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190133948-A1 FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES FUS, NSF, PGF TSHR 4478/4885HIF1A 1064/4885FAAH 1061/4885
US-11364200-B2 FUS, NSF, MATR3 TSHR 4775/4885HIF1A 1070/4885FAAH 896/4885
US-11318099-B2 FUS, NSF, MATR3 TSHR 4775/4885HIF1A 1070/4885FAAH 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.